Stockscreener 앱 받기
0.4629
3.37%
0.0151
시간 외 거래:
.46
-0.0029
-0.63%
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
FMR LLC Significantly Reduces Holdings in aTyr Pharma Inc - GuruFocus
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
aTyr Pharma Company Profile & Introduction - Moomoo
aTyr Pharma Granted Nasdaq Extension to Regain Compliance - The Globe and Mail
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide - simplywall.st
aTyr Pharma Received Notice of Noncompliance - TradingView
aTyr Pharma (NASDAQ: ATYR) wins second Nasdaq deadline to fix sub-$1 share price - Stock Titan
aTyr Pharma (ATYR) Faces Steep Decline as Shares Test Key Support ZoneJelly Roll Trade - The League of Women Voters of Texas
FMR LLC discloses 5.94M-share stake in ATYR (NASDAQ: ATYR) Amendment No.14 - Stock Titan
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis - TipRanks
aTyr Pharma (ATYR) Price Target Decreased by 37.13% to 6.48 - MSN
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data - TipRanks
aTyr Pharma (ATYR) refocuses efzofitimod after EFZO-FIT miss with new Phase 3 sarcoidosis trial - Stock Titan
aTyr Pharma Inc stock (US53227K1025): Insider buying and price gains draw focus - AD HOC NEWS
aTYR Pharma director Paul Schimmel buys $49,630 in common stock By Investing.com - Investing.com Australia
aTYR Pharma director Paul Schimmel buys $49,630 in common stock - Investing.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Director at aTyr Pharma (NASDAQ: ATYR) adds 100K shares - Stock Titan
aTyr Pharma plans new phase 3 trial for pulmonary sarcoidosis drug - Investing.com Nigeria
aTyr Pharma (ATYR) Slips 1.22%, Approaching Key Support at $0.46Total Put Call - newsline.com
aTyr Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Some Relief Amid Pipeline DevelopmentBasic EPS Analysis - newsline.com
Why Is aTyr Stock Falling Today? - MSN
aTyr Pharma (ATYR) Stock Forecast & Analyst Ratings - Moomoo
aTyr Pharma stock (US53227K1025): clinical pipeline update keeps biotech in focus - AD HOC NEWS
ATyr Pharma revamps efzofitimod path with new phase III sarcoidosis trial - MSN
Freedom Capital Markets Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $3.5 - Moomoo
ATYR Upgraded by Freedom Broker -- Price Target Raised to $3.50 - GuruFocus
ATyr Pharma Raised to Buy From Hold by Freedom Broker - Moomoo
ATyr Pharma Price Target Raised to $3.50/Share From $1.00 by Freedom Broker - Moomoo
aTyr Pharma upgraded to Buy from Hold at Freedom Broker - TipRanks
Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma stock (US0021202025): fresh quarterly loss keeps biotech in focus - AD HOC NEWS
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Number of shareholders of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Number of shareholders of aTyr Pharma, Inc. – LS:A2PM86 - TradingView
aTyr Pharma Inc stock (US53227K1025): biotech under pressure as short interest jumps and earnings su - AD HOC NEWS
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
[10-Q] aTYR PHARMA INC Quarterly Earnings Report - Stock Titan
aTyr: Advancing Efzofitimod for Pulmonary Sarcoidosis - GuruFocus
aTyr Pharma Inc options imply 30.5% move in share price post-earnings - TipRanks
aTyr Pharma Reports Q1 2026 Results, Advances Efzofitimod Phase 3 for Pulmonary Sarcoidosis After FDA Meeting - Minichart
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
aTyr Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update - The Manila Times
Atyr Pharma: Q1 Earnings Snapshot - marketscreener.com
aTyr Pharma (NASDAQ: ATYR) details Q1 2026 loss and Phase 3 plan - Stock Titan
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III ResultsSlideshow (NASDAQ:ATYR) 2026-05-14 - Seeking Alpha
2.60%
0.94%
자본화:
|
볼륨(24시간):